TSG6 Composition for treating metastatic solid cancer comprising TSG6 inhibitor

The present invention relates to a use of TSG6 shRNA as a therapeutic agent for metastatic solid cancer. More specifically, the present invention can be usefully used for treating cancer in which metastasis occurs by PLK1, which is known to be overexpressed, especially in cancer, and the active form...

Full description

Saved in:
Bibliographic Details
Main Authors YIM HYUNG SHIN, SHIN SOL BI, JANG HAY RAN
Format Patent
LanguageEnglish
Korean
Published 23.12.2021
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a use of TSG6 shRNA as a therapeutic agent for metastatic solid cancer. More specifically, the present invention can be usefully used for treating cancer in which metastasis occurs by PLK1, which is known to be overexpressed, especially in cancer, and the active form thereof, or by TGF-beta/Smad signaling, by reducing proliferation, migration, and invasiveness of metastatic cancer cells through gene therapy that inhibits TSG6 mRNA expression. 본 발명은 TSG6 shRNA의 전이성 고형암 치료제 용도에 관한 것으로, 보다 상세하게는, 본 발명은 TSG6 mRNA 발현을 억제하는 유전자 치료를 통해 전이성 암세포의 증식, 이동성 및 침습성을 감소시킴으로써 특히 암에서 과발현되는 것으로 알려진 PLK1과 그 활성형 또는 TGF-beta/Smad 신호전달에 의하여 전이가 일어나는 암의 치료에 유용하게 사용될 수 있다.
Bibliography:Application Number: KR20200072862